NYC 2017 ICIRC

The importance of immunology in tumor response to radiotherapy represents a major opportunity for our discipline. Novel therapies have emerged which target the immune cells. Combinations of such therapies to radiotherapy might translate into better local tumor control rates and also into better distant control given the possibility to use radiotherapy as an immunological enhancer of the anti-tumor immune response. Drugs targeting the immune checkpoints such as PD-1, PD-L1, and CTLA-4 blockers are among the first agents; moreover, several other agents are also in development. Thus, the selection of the optimal combination based on a sound rationale and proper patient selection will be key.

Partner’s website and additional information: http://www.radio-immuno.siricsocrate.fr/ 

Poster Abstract Format (submission period closed)

• NO phone numbers, hyperlinks, keyword lists,  or figures.
• Maximum of 500 words (not including title and authors).
• Paragraph breaks between Title, Author & Institute, abstract body, funding and references
• Include: Background, Brief methods, Results and Conclusions
• File must be saved as Word file
• Arial, 11 point, black font
• For Greek and Scientific symbols, use the Symbol option under the Insert tab in Microsoft Word (or equivalent option in other applications)
• Single spacing, one-inch margins, left justified
• One abstract per submitting author per meeting. Presenting author must be underlined.

Please indicate if the abstract presenter is a student/post-doc or resident. Abstracts submitted  by  student/post-doc or residents will be reviewed by a special committee and the best abstract

In two categories, Basic/Translational and Clinical research will receive a travel award of $500 (the award will be announced at the meeting during the poster session). 

As of 9/12/17 at 3 pm Eastern time, the 2017 conference has sold out. If you are interested in being notified of registration cancellations; please contact Jane Yuen at Jay2009@med.cornell.edu

For information on the 2018 Conference, please visit http://www.radio-immuno.siricsocrate.fr/en/

icirc_final_9-20-2017.pdf

THURSDAY, September 21st, 2017

Lewis C. Cantley, PhD; Gary Koretzky, MD, PhD
Weill Cornell Medical College, NY, USA

Silvia Formenti, MD
Weill Cornell Medical College, NY, USA

Karolina Palucka, MD, PhD
The Jackson Laboratory, CT, USA

Alan Frey, PhD
New York University, School of Medicine, NY, USA

Charles Drake, MD, PhD

Columbia University Medical Center, NY, USA

Timothy A. Chan, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Michael Postow, MD
Memorial Sloan Kettering Cancer Center, NY, USA

Robert Vonderheide, MD, DPhil
University of Pennsylvania, PA, USA

Sandra Demaria, MD
Weill Cornell Medical College, NY, USA

Jean-Luc Perfettini, MBBS
Institut Gustave Roussy, Paris, France

Lorenzo Galluzzi, PhD
Weill Cornell Medical College, NY, USA

Danielle M. Luissier, PhD 
Washington University, St Louis, USA

Michele Mondini, PhD
Institut Gustave Roussy, Paris, France

Eric Deutsch, MD, PhD
Institut Gustave Roussy, Paris, France

Alexandre Boissonnas, PhD
Inserm CIMI, Paris, France

Erik Wennerberg, PhD
Weill Cornell Medical College, NY, USA

FRIDAY, September 22nd, 2017

William H. McBride, PhD, DSc

UCLA, CA, USA

David Brenner, PhD, DSc
Columbia University Medical Center, NY, USA

Silvia Formenti, MD
Weill Cornell Medical College, NY, USA

Peter Huber, MD
German Cancer Research Center DKFZ, Heidelberg, Germany

Joshua Brody, MD
Ruttenberg Treatment Center, NY, USA

Tim Illidge, BSc, PhD, MB, BS, DRCOG, MRCP, FRCP, FRCPath
Institute of Cancer Sciences, University of Manchester, UK

Ralph Weichselbaum, MD
University of Chicago, IL, USA

Paul Sondel, MD, PhD
University of Wisconsin, School of Medicine and Public Health, WI, USA

Chandan Guha, MBBS, PhD
Albert Einstein College of Medicine, NY, USA

Claire Vanpouille-Box, PhD
Weill Cornell Medical College, NY, USA

Karolina Palucka, MD, PhD
The Jackson Laboratory, CT, USA

Giorgio Trinchieri, MD
National Cancer Institute, MD, USA

Elizabeth Repasky, PhD
Roswell Park Cancer Institute, NY, USA

SATURDAY, September 23rd, 2017

Philippe Lambin, MD, PhD

‎University of Maastricht and MAASTRO Clinic, Maastricht, NL

Oliver Elemento, PhD
Weill Cornell Medical College, NY, USA

Victor H. Engelhard, PhD
University of Virginia, School of Medicine, VA, USA

James W. Welsh, MD
University of Texas, MD Anderson Cancer Center, TX, USA

Kevin Harrington, PhD
The Institute of Cancer Research, London, UK

David Raben, MD
University of Colorado, Hospital Cancer Center, CO, USA